Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Phase 1b Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Systemic Sclerosis (SSc) Refractory to Standard Therapy

NCT07854483 is registered in ClinicalTrials.gov with AbelZeta Inc. as lead sponsor.

NCT NCT07854483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07854483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Phase 1b Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Systemic Sclerosis (SSc) Refractory to Standard Therapy
Lead sponsor
AbelZeta Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
March 31, 2030
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis, systemic sclerosis (scleroderma), systemic sclerosis (ssc), systemic sclerosis - 2013 acr/eular classification criteria, systemic sclerosis pulmonary, systemic sclerosis with lung involvement